Exhibits antifungal and cytotoxic activity against some tumor cell lines partly attributed to inhibition of Ras-inducible genes. Inhibits proliferation of mouse and human T cells and modulates production of cytokines during T cell activation. Facilitates the ubiquitinylation process of cyclin D1. Has been identified as a potent and selective inhibitor of threonine/tyrosine-specific kinase, MEK, and other protein kinases that contain a conserved cysteine residue in the ATP-binding site in both in vitro and in vivo studies. Hypothemycin inhibited the growth of HT29 and HCT116 cells in serum-free defined medium. IC50 at 0.078 mM and 0.90 mM, respectively.
Hypothemycin concurrently inhibitis Kit- and FcεRI-mediated signaling.
Product Details
| Formula: | C19H22O8 |
| |
| MW: | 378.4 |
| |
| Source: | Isolated from Phoma sp. |
| |
| CAS: | 76958-67-3 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO or acetone; insoluble in methanol or water. |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. |
| |
| Handling: | After reconstitution protect from light at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Hypothemycin inhibits tumor necrosis factor-α production by tristetraprolin-dependent down-regulation of mRNA stability in lipopolysaccharide-stimulated macrophages: K.H. Park, et al.; Int. Immunopharmacol.
29, 863 (2015),
Application(s): Effects of hypothemycin on tumor necrosis factor-α production in macrophages,
Abstract;
The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells: H. Fukazawa, et al.; Biol. Pharm. Bull.
33, 168 (2010),
Abstract;
Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation: B.M. Jensen, et al.; J. Pharmacol. Exp. Ther.
324, 128 (2008),
Abstract;
Chemistry and biology of resorcylic acid lactones: N. Winssinger & S. Barluenga; Chem. Commun. (Camb.)
1, 22 (2007), (Review),
Abstract;
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides: A. Schirmer, et al.; PNAS
103, 4234 (2006),
Abstract;
Full Text
Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor: H. Tanaka, et al.; Jpn. J. Cancer Res.
90, 1139 (1999),
Abstract;
Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation: R. Camacho, et al.; Immunopharmacology
44, 255 (1999),
Abstract;
Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK: A. Zhao, et al.; J. Antibiot.
52, 1086 (1999),
Abstract;
Suppression of oncogenic transformation by hypothemycin associated with accelerated cyclin D1 degradation through ubiquitin-proteasome pathway: H. Sonoda, et al.; Life Sci.
65, 381 (1999),
Abstract;
Revised structure and stereochemistry of hypothemycin: T. Agatsuma et al.; Chem. Pharm. Bull. 41, 373 (1993),
Metabolites of pyrenomycetes. XIV: Structure and partial stereochemistry of the antibiotic macrolides hypothemycin and dihydrohypothemycin: M.S.R. Nair, et al.; Tetrahedron 37, 2445 (1981),
Metabolites of pyrenomycetes XIII: Structure of (+) hypothemycin, an antibiotic macrolide from hypomyces trichothecoides: M.S.R. Nair & S.T. Carey; Tetrahedron Lett. 21, 2011 (1980),
